## I Claim:

1. A stereospecific synthesis of optically pure trans (E) isomer of coenzyme Q 10 having the formula

Ubiquinone

which comprises extracting solanesol from tobacco dust and using said solanesol as the starting material for carrying out the following sequence of reactions

Solanesylacetone

$$CN_3$$
 $H \{CH_2 - C = CH - CH_2\}_q OH \xrightarrow{PB_3} \left[ H \{CH_2 - C = CH - CH_2\}_q B_r \right]$ 

solanesol

$$CH_3$$
 $CH_3$ 
 $H\{CH_2-C=CH-CH_2\}_qCH_2-C=O$ 

solonesylacetone

 $CH_2=CHM_9Br$ 
 $CH_3$ 
 $CH_3$ 

$$CH_3$$
 $CH_3$ 
 $CH_2-C=CH-CH_2$ 
 $CH_3-CH_3-CH=CH_2$ 
 $CH_3$ 
 $CH_3-CH=CH_3$ 
 $CH_3$ 
 $CH_3$ 

13

separately carrying out the following reactions:

## 2,3,6 - Tribromo- 4 - methylphenol

## z, 3,4,5 - Tetramethoxy toluene

## 2, 3 - Dimethoxy-5- methylhydroquinone

thereafter reacting the isodecaprenol and 2, 3,-dimethoxy-5-methyl-hydroquinone to form the optical pure ubiquinone

$$CH_3 O CH_3 CH_3 CH_3 CH_2 - C-CH = CH_2$$

$$CH_3 O CH_3 CH_2 - C-CH = CH_2$$

$$O CH_3 CH_3 CH_2 - C-CH = CH_2$$

1,3 - dimethoxy-5-methylhydroquinone isodecaprenol

Ubiquinone

- Method of treating impaired or damaged tissue in humans and animals which comprises administering a composition comprising as the principal active ingredient a therapeutically effective amount of optically pure trans
   (E) isomer of coenzyme Q 10 (2,3 dimethoxy 5 methyl 6 decaprenyl beyzoquinone) in admixture with a pharmaceutically acceptable carrier.
  - 3. The method of claim 2 wherein said composition is administered orally.
  - The method of claim 3 wherein said composition is administered in an amount of 15-400 mg pro die.
  - The method of claim 3 wherein said composition is administered in an amount of 100-200 mg pro die.
  - The method of claim 3 wherein said composition is administered in an amount of 15-30 mg pro die.
  - 7. The method of claim 3 wherein said composition is in tablet form.
  - 8. The method of claim 3 wherein said composition is in liquid form.
  - The method of claim 2 wherein said composition is administered by topical application.
  - 10. The method of claim 9 wherein said composition contains the optically pure coenzyme Q 10 in an amount of 0.1-10%.
  - 11. The method of claim 9 wherein said composition contains the optically pure coenzyme Q 10 in an amount of 0.25-1%.

- 12. The method of claim 9 wherein said composition is to be used as a cosmetic and said optically pure coenzyme Q 10 is present in an amount of 0.0001 to 0.1%.
- 13. The method of claim 2 wherein said pharmaceutically acceptable carrier is a vegetable oil.
- 14. The method of claim 9 wherein said composition is formulated as a paste, cream, ointment, gel, lotion or unguent.
- 15. The stereospecific optically pure trans (E) isomer of coenzyme Q 10 produced by the process of claim 1.